our mission
To save lives, reduce healthcare costs, and eliminate unnecessary anxiety for women with a painless, safe, and accurate breast exam.
our vision
To become the global market leader in the non-invasive early detection of cancer and the reliable monitoring of cancer treatment efficacy.
about us
At EosDx, we are creating a new modality to revolutionize cancer detection. The first company to develop compact bio-crystallography technology as a diagnostic service, EosDx is powered by advanced machine learning to identify pre-symptomatic cancer, accurately, objectively, and painlessly.
The extracellular matrix (ECM) is a network of extracellular macromolecules and minerals such as collagen, enzymes, keratin, and glycoproteins that provide structural and biochemical support to surrounding cells. In the human body, the ECM contains biomarkers that provide real-time information about the body’s health status. Bio-crystallography’s subatomic level resolution enables the precise interrogation of the ECM and the detailed assessment of certain biomarkers. This enables the non-invasive and extremely accurate early detection and characterization of malignancies. Furthermore, this opens the door to the efficient assessment of the trajectory of disease and treatment efficacy.
Learn more about the problems we are solving from one of our clinical advisors, Dr. Rachel Brem
board of directors
Left to Right: Pavel Lazarev, PhD, John Pavlidis, Rachel Brem, MD, David de Weese, Marilyn Simons, PhD
